Business News

July 31, 2017 – (BioLife) – BioLife Solutions, Inc. announced it has executed a long term supply agreement with NASDAQ-listed Celyad, a leader in the discovery and development of CAR-T cell therapies. BioLife's CryoStor clinical grade cell freeze media is incorporated into Celyad's manufacturing process for its Natural Killer Receptor based T-Cell (NKR-T) platform. 
July 13, 2017 – (Novartis) – "The panel's unanimous recommendation in favor of CTL019 moves us closer to potentially delivering the first-ever commercially approved CAR-T cell therapy to patients in need," said Bruno Strigini, CEO, Novartis Oncology. "We're very proud to be expanding new frontiers in cancer treatment by advancing immunocellular therapy for children and young adults with r/r B-cell ALL and other critically ill patients who have limited options. We look forward to working with the FDA as they complete their review." 
July 10, 2017 – (Broad) – If other key patent holders join, the pool would expand access and streamline non-exclusive licensing for commercial use. 
July 10, 2017 – (CRISPR) – CRISPR Therapeutics (NASDAQ:CRSP) and Neon Therapeutics announced a research collaboration to explore the combination of each company’s proprietary technologies to develop novel T cell therapies. 
July 5, 2017 – (MiMedx) – MiMedx and AvKARE began planning the wind-down of the contract in 2015, leading up to the final expiration of the contract on June 30, 2017. In 2012, MiMedx entered into a partnership with AvKARE in which AvKARE served as a distributor of MiMedxproducts only to the federal government. 
July 5, 2017 – (Opexa) – Opexa Therapeutics, Inc. and Acer Therapeutics Inc. announced they have entered into a definitive merger agreement. In conjunction with the proposed merger, an investor syndicate led by TVM Capital Life Sciences and comprised of existing Acer investors and new investors has committed to invest approximately $15.7 million in Acer (including through a conversion of approximately $5.7 million in outstanding convertible notes) immediately prior to closing of the proposed merger. 
July 5, 2017 – (Censo) – In collaboration with the Leeds Institute of Cancer and Pathology at the University of Leeds, Censo will create induced pluripotent stem cells from brain tumours removed from patients as part of their clinical treatment. The stem cells will be used in the project to identify drugs which could prevent or limit the growth of brain cancer cells. 

Pages